| Name | Title | Contact Details |
|---|
CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company`s research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi`s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.
The Center for Breakthrough Medicines is the Worlds Largest and Most Advanced Single Solution Cell and Gene Therapy Contract Development and Manufacturing Organization. Period.
We are industry-leading experts in Bio Convergence. By combining the power of biology, engineering and computer science, we create the future of health. We extend the boundaries of what`s possible to give people better and healthier lives. Products from the BICO Group are trusted by more than 2,00 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 1800 publications. BICO is creating the future of health. Visit bico.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.
MicroDose Therapeutx is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Genomics is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.